Skip to main content
Erschienen in: Neurotoxicity Research 4/2016

01.11.2016 | Review

Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics

verfasst von: Ankit Shah, Mohitkumar R. Gangwani, Nitish S. Chaudhari, Alexy Glazyrin, Hari K. Bhat, Anil Kumar

Erschienen in: Neurotoxicity Research | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Despite the advent of highly active antiretroviral therapy (HAART), HIV-associated neurological disorders (HAND) remain a major challenge in human immunodeficiency virus (HIV) treatment. The early implementation of HAART in the infected individuals helps suppress the viral replication in the plasma and other compartments. Several studies also report the beneficial effect of drugs that successfully penetrate central nervous system (CNS). However, recent data in both clinical setup and in in vitro studies indicate CNS toxicity of the antiretrovirals (ARVs). Although the evidence is limited, correlation between prolonged use of ARVs and neurotoxicity strongly suggests that it is essential to study the underlying mechanisms responsible for such toxicity. Furthermore, closer attention toward clinical outcomes is required to screen various ARV regimens for their association with HAND and other comorbidities. A growing body of literature also indicates a possible role of accelerated aging in the antiretroviral therapy-associated neurotoxicity. Lastly, owing to high pill burden, multiple drugs in the HIV treatment also invite a possible role of drug–drug interaction via various cytochrome P450 enzymes. The particular emphasis of this review is to highlight the need to identify alternative approaches in reducing the CNS toxicity of the ARV drugs in HIV-infected individuals.
Literatur
Zurück zum Zitat Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood–brain barrier. Neurobiol Dis 37:13–25PubMedCrossRef Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ (2010) Structure and function of the blood–brain barrier. Neurobiol Dis 37:13–25PubMedCrossRef
Zurück zum Zitat Akay C, Cooper M, Odeleye A, Jensen BK, White MG, Vassoler F, Gannon PJ, Mankowski J, Dorsey JL, Buch AM, Cross SA, Cook DR, Pena MM, Andersen ES, Christofidou-Solomidou M, Lindl KA, Zink MC, Clements J, Pierce RC, Kolson DL, Jordan-Sciutto KL (2014) Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neurovirol 20:39–53. doi:10.1007/s13365-013-0227-1 PubMedPubMedCentralCrossRef Akay C, Cooper M, Odeleye A, Jensen BK, White MG, Vassoler F, Gannon PJ, Mankowski J, Dorsey JL, Buch AM, Cross SA, Cook DR, Pena MM, Andersen ES, Christofidou-Solomidou M, Lindl KA, Zink MC, Clements J, Pierce RC, Kolson DL, Jordan-Sciutto KL (2014) Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system. J Neurovirol 20:39–53. doi:10.​1007/​s13365-013-0227-1 PubMedPubMedCentralCrossRef
Zurück zum Zitat András IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M (2003) HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 74:255–265PubMedCrossRef András IE, Pu H, Deli MA, Nath A, Hennig B, Toborek M (2003) HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res 74:255–265PubMedCrossRef
Zurück zum Zitat András IE, Pu H, Tian J, Deli MA, Nath A, Hennig B, Toborek M (2005) Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab 25:1159–1170PubMedCrossRef András IE, Pu H, Tian J, Deli MA, Nath A, Hennig B, Toborek M (2005) Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab 25:1159–1170PubMedCrossRef
Zurück zum Zitat András IE, Toborek M (2011) HIV-1-induced alterations of claudin-5 expression at the blood–brain barrier level. Methods Mol Biol 762:355–370PubMedPubMedCentralCrossRef András IE, Toborek M (2011) HIV-1-induced alterations of claudin-5 expression at the blood–brain barrier level. Methods Mol Biol 762:355–370PubMedPubMedCentralCrossRef
Zurück zum Zitat Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE (2006) Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 111:529–538. doi:10.1007/s00401-006-0037-0 PubMedCrossRef Anthony IC, Ramage SN, Carnie FW, Simmonds P, Bell JE (2006) Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol 111:529–538. doi:10.​1007/​s00401-006-0037-0 PubMedCrossRef
Zurück zum Zitat Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799. doi:10.1212/01.WNL.0000287431.88658.8b PubMedPubMedCentralCrossRef Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799. doi:10.​1212/​01.​WNL.​0000287431.​88658.​8b PubMedPubMedCentralCrossRef
Zurück zum Zitat Antiretroviral Therapy Cohort C (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372:293–299. doi:10.1016/S0140-6736(08)61113-7 CrossRef Antiretroviral Therapy Cohort C (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372:293–299. doi:10.​1016/​S0140-6736(08)61113-7 CrossRef
Zurück zum Zitat Apostolova N, Funes HA, Blas-Garcia A, Alegre F, Polo M, Esplugues JV (2015) Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells. J Infect Dis 211:1953–1958. doi:10.1093/infdis/jiu825 PubMedCrossRef Apostolova N, Funes HA, Blas-Garcia A, Alegre F, Polo M, Esplugues JV (2015) Involvement of nitric oxide in the mitochondrial action of efavirenz: a differential effect on neurons and glial cells. J Infect Dis 211:1953–1958. doi:10.​1093/​infdis/​jiu825 PubMedCrossRef
Zurück zum Zitat Atluri VSR, Hidalgo M, Samikkannu T, Kurapati KRV, Jayant RD, Sagar V, Nair MP (2015) Effect of human immunodeficiency virus on blood–brain barrier integrity and function: an update. Front Cell Neurosci 9:212PubMedPubMedCentralCrossRef Atluri VSR, Hidalgo M, Samikkannu T, Kurapati KRV, Jayant RD, Sagar V, Nair MP (2015) Effect of human immunodeficiency virus on blood–brain barrier integrity and function: an update. Front Cell Neurosci 9:212PubMedPubMedCentralCrossRef
Zurück zum Zitat Auclair M, Afonso P, Capel E, Caron-Debarle M, Capeau J (2014) Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin. Antivir Ther 19:773–782PubMedCrossRef Auclair M, Afonso P, Capel E, Caron-Debarle M, Capeau J (2014) Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin. Antivir Ther 19:773–782PubMedCrossRef
Zurück zum Zitat Azzam R, Lal L, Goh SL, Kedzierska K, Jaworowski A, Naim E, Cherry CL, Wesselingh SL, Mills J, Crowe SM (2006) Adverse effects of antiretroviral drugs on HIV-1-infected and -uninfected human monocyte-derived macrophages. J Acquir Immune Defic Syndr 42:19–28. doi:10.1097/01.qai.0000214809.83218.88 PubMed Azzam R, Lal L, Goh SL, Kedzierska K, Jaworowski A, Naim E, Cherry CL, Wesselingh SL, Mills J, Crowe SM (2006) Adverse effects of antiretroviral drugs on HIV-1-infected and -uninfected human monocyte-derived macrophages. J Acquir Immune Defic Syndr 42:19–28. doi:10.​1097/​01.​qai.​0000214809.​83218.​88 PubMed
Zurück zum Zitat Baliga RS, Liu C, Hoyt DG, Chaves AA, Bauer JA (2004) Vascular endothelial toxicity induced by HIV protease inhibitor. Cardiovasc Toxicol 4:199–206PubMedCrossRef Baliga RS, Liu C, Hoyt DG, Chaves AA, Bauer JA (2004) Vascular endothelial toxicity induced by HIV protease inhibitor. Cardiovasc Toxicol 4:199–206PubMedCrossRef
Zurück zum Zitat Ballabh P, Braun A, Nedergaard M (2004) The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16:1–13PubMedCrossRef Ballabh P, Braun A, Nedergaard M (2004) The blood–brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis 16:1–13PubMedCrossRef
Zurück zum Zitat Banks WA, Erickson MA (2010) The blood–brain barrier and immune function and dysfunction. Neurobiol Dis 37:26–32PubMedCrossRef Banks WA, Erickson MA (2010) The blood–brain barrier and immune function and dysfunction. Neurobiol Dis 37:26–32PubMedCrossRef
Zurück zum Zitat Bazzoni G, Dejana E (2004) Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 84:869–901PubMedCrossRef Bazzoni G, Dejana E (2004) Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 84:869–901PubMedCrossRef
Zurück zum Zitat Becker JT, Lopez OL, Dew MA, Aizenstein HJ (2004) Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 18(Suppl 1):S11–S18PubMedCrossRef Becker JT, Lopez OL, Dew MA, Aizenstein HJ (2004) Prevalence of cognitive disorders differs as a function of age in HIV virus infection. AIDS 18(Suppl 1):S11–S18PubMedCrossRef
Zurück zum Zitat Blas-Garcia A, Polo M, Alegre F, Funes HA, Martinez E, Apostolova N, Esplugues JV (2014) Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz. J Antimicrob Chemother 69:2995–3000. doi:10.1093/jac/dku262 PubMedCrossRef Blas-Garcia A, Polo M, Alegre F, Funes HA, Martinez E, Apostolova N, Esplugues JV (2014) Lack of mitochondrial toxicity of darunavir, raltegravir and rilpivirine in neurons and hepatocytes: a comparison with efavirenz. J Antimicrob Chemother 69:2995–3000. doi:10.​1093/​jac/​dku262 PubMedCrossRef
Zurück zum Zitat Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Di Cintio E, Martinelli C, Faggion I, Landonio S, Quirino T (2000) Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 23:236–245PubMedCrossRef Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F, Ghiselli G, Gabbuti A, Di Cintio E, Martinelli C, Faggion I, Landonio S, Quirino T (2000) Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. J Acquir Immune Defic Syndr 23:236–245PubMedCrossRef
Zurück zum Zitat Bressani RF, Nowacek AS, Singh S, Balkundi S, Rabinow B, McMillan J, Gendelman HE, Kanmogne GD (2011) Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology 5:592–605. doi:10.3109/17435390.2010.541292 PubMedCrossRef Bressani RF, Nowacek AS, Singh S, Balkundi S, Rabinow B, McMillan J, Gendelman HE, Kanmogne GD (2011) Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. Nanotoxicology 5:592–605. doi:10.​3109/​17435390.​2010.​541292 PubMedCrossRef
Zurück zum Zitat Brown LA, Jin J, Ferrell D, Sadic E, Obregon D, Smith AJ, Tan J, Giunta B (2014) Efavirenz promotes beta-secretase expression and increased Abeta1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND). PLoS One 9:e95500. doi:10.1371/journal.pone.0095500 PubMedPubMedCentralCrossRef Brown LA, Jin J, Ferrell D, Sadic E, Obregon D, Smith AJ, Tan J, Giunta B (2014) Efavirenz promotes beta-secretase expression and increased Abeta1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND). PLoS One 9:e95500. doi:10.​1371/​journal.​pone.​0095500 PubMedPubMedCentralCrossRef
Zurück zum Zitat Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernan MA, Collaboration H-C (2014) Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 83:134–141. doi:10.1212/WNL.0000000000000564 PubMedPubMedCentralCrossRef Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernan MA, Collaboration H-C (2014) Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 83:134–141. doi:10.​1212/​WNL.​0000000000000564​ PubMedPubMedCentralCrossRef
Zurück zum Zitat Carvalhal A, Gill MJ, Letendre SL, Rachlis A, Bekele T, Raboud J, Burchell A, Rourke SB, the Centre for Brain Health in HA (2015) Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study. J Neurovirol. doi:10.1007/s13365-015-0404-5 PubMed Carvalhal A, Gill MJ, Letendre SL, Rachlis A, Bekele T, Raboud J, Burchell A, Rourke SB, the Centre for Brain Health in HA (2015) Central nervous system penetration effectiveness of antiretroviral drugs and neuropsychological impairment in the Ontario HIV Treatment Network Cohort Study. J Neurovirol. doi:10.​1007/​s13365-015-0404-5 PubMed
Zurück zum Zitat Cespedes MS, Aberg JA (2006) Neuropsychiatric complications of antiretroviral therapy. Drug Saf 29:865–874PubMedCrossRef Cespedes MS, Aberg JA (2006) Neuropsychiatric complications of antiretroviral therapy. Drug Saf 29:865–874PubMedCrossRef
Zurück zum Zitat Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD (2008) STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood–brain barrier. Blood 111:2062–2072PubMedPubMedCentralCrossRef Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD (2008) STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood–brain barrier. Blood 111:2062–2072PubMedPubMedCentralCrossRef
Zurück zum Zitat Chen C, Lu X-H, Yan S, Chai H, Yao Q (2005) HIV protease inhibitor ritonavir increases endothelial monolayer permeability. Biochem Biophys Res Commun 335:874–882PubMedCrossRef Chen C, Lu X-H, Yan S, Chai H, Yao Q (2005) HIV protease inhibitor ritonavir increases endothelial monolayer permeability. Biochem Biophys Res Commun 335:874–882PubMedCrossRef
Zurück zum Zitat Cherry CL, Mobarok M, Wesselingh SL, Fain R, Weinstock S, Tachedjian G, Srivastava S, Tyssen DP, Glass JD, Hooker DJ (2010) Ubisol-AquaTM: coenzyme Q10 prevents antiretroviral toxic neuropathy in an in vitro model. CHR 8:232–239. doi:10.2174/157016210791111106 CrossRef Cherry CL, Mobarok M, Wesselingh SL, Fain R, Weinstock S, Tachedjian G, Srivastava S, Tyssen DP, Glass JD, Hooker DJ (2010) Ubisol-AquaTM: coenzyme Q10 prevents antiretroviral toxic neuropathy in an in vitro model. CHR 8:232–239. doi:10.​2174/​1570162107911111​06 CrossRef
Zurück zum Zitat Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25:F7–12. doi:10.1097/QAD.0b013e328345766f PubMedCrossRef Cohen C, Elion R, Ruane P, Shamblaw D, DeJesus E, Rashbaum B, Chuck SL, Yale K, Liu HC, Warren DR, Ramanathan S, Kearney BP (2011) Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25:F7–12. doi:10.​1097/​QAD.​0b013e328345766f​ PubMedCrossRef
Zurück zum Zitat Dalakas MC, Semino-Mora C, Leon-Monzon M (2001) Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Investig 81:1537–1544PubMedCrossRef Dalakas MC, Semino-Mora C, Leon-Monzon M (2001) Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2′3′-dideoxycytidine (ddC). Lab Investig 81:1537–1544PubMedCrossRef
Zurück zum Zitat Divi RL, Einem TL, Fletcher SL, Shockley ME, Kuo MM, St Claire MC, Cook A, Nagashima K, Harbaugh SW, Harbaugh JW, Poirier MC (2010) Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs). Toxicol Sci 118:191–201. doi:10.1093/toxsci/kfq235 PubMedPubMedCentralCrossRef Divi RL, Einem TL, Fletcher SL, Shockley ME, Kuo MM, St Claire MC, Cook A, Nagashima K, Harbaugh SW, Harbaugh JW, Poirier MC (2010) Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs). Toxicol Sci 118:191–201. doi:10.​1093/​toxsci/​kfq235 PubMedPubMedCentralCrossRef
Zurück zum Zitat Dragovic G, Jevtovic D (2003) Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. Antivir Chem Chemother 14:281–284PubMedCrossRef Dragovic G, Jevtovic D (2003) Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. Antivir Chem Chemother 14:281–284PubMedCrossRef
Zurück zum Zitat Du Pasquier RA, Jilek S, Kalubi M, Yerly S, Fux CA, Gutmann C, Cusini A, Gunthard HF, Cavassini M, Vernazza PL, Swiss HIVCS (2013) Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS 27:203–210. doi:10.1097/QAD.0b013e32835a9a4a PubMedCrossRef Du Pasquier RA, Jilek S, Kalubi M, Yerly S, Fux CA, Gutmann C, Cusini A, Gunthard HF, Cavassini M, Vernazza PL, Swiss HIVCS (2013) Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS 27:203–210. doi:10.​1097/​QAD.​0b013e32835a9a4a​ PubMedCrossRef
Zurück zum Zitat Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190–194PubMedPubMedCentralCrossRef Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190–194PubMedPubMedCentralCrossRef
Zurück zum Zitat Eagling VA, Wiltshire H, Whitcombe IW, Back DJ (2002) CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1–17PubMedCrossRef Eagling VA, Wiltshire H, Whitcombe IW, Back DJ (2002) CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavir in vitro. Xenobiotica 32:1–17PubMedCrossRef
Zurück zum Zitat Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McArthur JC, Simpson DM, Ake C, Collier AC, Gelman BB, McCutchan JA, Morgello S, Grant I, Group C (2008) Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 64:566–572. doi:10.1002/ana.21484 PubMedPubMedCentralCrossRef Ellis RJ, Marquie-Beck J, Delaney P, Alexander T, Clifford DB, McArthur JC, Simpson DM, Ake C, Collier AC, Gelman BB, McCutchan JA, Morgello S, Grant I, Group C (2008) Human immunodeficiency virus protease inhibitors and risk for peripheral neuropathy. Ann Neurol 64:566–572. doi:10.​1002/​ana.​21484 PubMedPubMedCentralCrossRef
Zurück zum Zitat Fiala M, Murphy T, MacDougall J, Yang W, Luque A, Iruela-Arispe L, Cashman J, Buga G, Byrns RE, Barbaro G (2004) HAART drugs induce mitochondrial damage and intercellular gaps and gp 120 causes apoptosis. Cardiovasc Toxicol 4:327–337PubMedCrossRef Fiala M, Murphy T, MacDougall J, Yang W, Luque A, Iruela-Arispe L, Cashman J, Buga G, Byrns RE, Barbaro G (2004) HAART drugs induce mitochondrial damage and intercellular gaps and gp 120 causes apoptosis. Cardiovasc Toxicol 4:327–337PubMedCrossRef
Zurück zum Zitat Fu W, Chai H, Yao Q, Chen C (2005) Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression JAIDS. J Acquir Immune Defic Syndr 39:152–158PubMed Fu W, Chai H, Yao Q, Chen C (2005) Effects of HIV protease inhibitor ritonavir on vasomotor function and endothelial nitric oxide synthase expression JAIDS. J Acquir Immune Defic Syndr 39:152–158PubMed
Zurück zum Zitat Fumaz CR, Gonzalez-Garcia M, Borras X, Munoz-Moreno JA, Perez-Alvarez N, Mothe B, Brander C, Ferrer MJ, Puig J, Llano A, Fernandez-Castro J, Clotet B (2012) Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment. Brain Behav Immun 26:568–572. doi:10.1016/j.bbi.2012.01.001 PubMedCrossRef Fumaz CR, Gonzalez-Garcia M, Borras X, Munoz-Moreno JA, Perez-Alvarez N, Mothe B, Brander C, Ferrer MJ, Puig J, Llano A, Fernandez-Castro J, Clotet B (2012) Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment. Brain Behav Immun 26:568–572. doi:10.​1016/​j.​bbi.​2012.​01.​001 PubMedCrossRef
Zurück zum Zitat Funes HA, Blas-Garcia A, Esplugues JV, Apostolova N (2015) Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines. J Antimicrob Chemother 70:2249–2254. doi:10.1093/jac/dkv098 PubMedCrossRef Funes HA, Blas-Garcia A, Esplugues JV, Apostolova N (2015) Efavirenz alters mitochondrial respiratory function in cultured neuron and glial cell lines. J Antimicrob Chemother 70:2249–2254. doi:10.​1093/​jac/​dkv098 PubMedCrossRef
Zurück zum Zitat Fung HB, Guo Y (2004) Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 26:352–378PubMedCrossRef Fung HB, Guo Y (2004) Enfuvirtide: a fusion inhibitor for the treatment of HIV infection. Clin Ther 26:352–378PubMedCrossRef
Zurück zum Zitat Galluzzi L, Pinti M, Troiano L, Prada N, Nasi M, Ferraresi R, Salomoni P, Mussini C, Cossarizza A (2005) Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir Ther 10:191–195PubMed Galluzzi L, Pinti M, Troiano L, Prada N, Nasi M, Ferraresi R, Salomoni P, Mussini C, Cossarizza A (2005) Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir Ther 10:191–195PubMed
Zurück zum Zitat Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA, study UKCHC (2011) Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 76:693–700. doi:10.1212/WNL.0b013e31820d8b0b PubMedPubMedCentralCrossRef Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Palfreeman A, Gompels M, Phillips AN, Sabin CA, study UKCHC (2011) Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology 76:693–700. doi:10.​1212/​WNL.​0b013e31820d8b0b​ PubMedPubMedCentralCrossRef
Zurück zum Zitat Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S (2007) Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and *26. Clin Infect Dis 45:1230–1237. doi:10.1086/522175 PubMedCrossRef Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H, Fujimoto K, Sato I, Ueda M, Horiba M, Hamaguchi M, Yamamoto M, Takata N, Kimura A, Koike T, Gejyo F, Matsushita S, Shirasaka T, Kimura S, Oka S (2007) Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6*6 and *26. Clin Infect Dis 45:1230–1237. doi:10.​1086/​522175 PubMedCrossRef
Zurück zum Zitat Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306PubMedCrossRef Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295–306PubMedCrossRef
Zurück zum Zitat Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, Jin J, Fernandez F, Tan J, Shytle RD (2011) Antiretroviral medications disrupt microglial phagocytosis of beta-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. Mol Brain 4:23. doi:10.1186/1756-6606-4-23 PubMedPubMedCentralCrossRef Giunta B, Ehrhart J, Obregon DF, Lam L, Le L, Jin J, Fernandez F, Tan J, Shytle RD (2011) Antiretroviral medications disrupt microglial phagocytosis of beta-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders. Mol Brain 4:23. doi:10.​1186/​1756-6606-4-23 PubMedPubMedCentralCrossRef
Zurück zum Zitat Glover M, Hebert VY, Nichols K, Xue SY, Thibeaux TM, Zavecz JA, Dugas TR (2014) Overexpression of mitochondrial antioxidant manganese superoxide dismutase (MnSOD) provides protection against AZT-or 3TC-induced endothelial dysfunction. Antivir Res 111:136–142PubMedPubMedCentralCrossRef Glover M, Hebert VY, Nichols K, Xue SY, Thibeaux TM, Zavecz JA, Dugas TR (2014) Overexpression of mitochondrial antioxidant manganese superoxide dismutase (MnSOD) provides protection against AZT-or 3TC-induced endothelial dysfunction. Antivir Res 111:136–142PubMedPubMedCentralCrossRef
Zurück zum Zitat Gomes MJ, Neves J, Sarmento B (2014) Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomed 9:1757–1769 Gomes MJ, Neves J, Sarmento B (2014) Nanoparticle-based drug delivery to improve the efficacy of antiretroviral therapy in the central nervous system. Int J Nanomed 9:1757–1769
Zurück zum Zitat Gongvatana A, Harezlak J, Buchthal S, Daar E, Schifitto G, Campbell T, Taylor M, Singer E, Algers J, Zhong J, Brown M, McMahon D, So YT, Mi D, Heaton R, Robertson K, Yiannoutsos C, Cohen RA, Navia B, Consortium HIVN (2013) Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. J Neurovirol 19:209–218. doi:10.1007/s13365-013-0162-1 PubMedPubMedCentralCrossRef Gongvatana A, Harezlak J, Buchthal S, Daar E, Schifitto G, Campbell T, Taylor M, Singer E, Algers J, Zhong J, Brown M, McMahon D, So YT, Mi D, Heaton R, Robertson K, Yiannoutsos C, Cohen RA, Navia B, Consortium HIVN (2013) Progressive cerebral injury in the setting of chronic HIV infection and antiretroviral therapy. J Neurovirol 19:209–218. doi:10.​1007/​s13365-013-0162-1 PubMedPubMedCentralCrossRef
Zurück zum Zitat Govindarajan R, Leung GP, Zhou M, Tse C-M, Wang J, Unadkat JD (2009) Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol 296:G910–G922PubMedPubMedCentralCrossRef Govindarajan R, Leung GP, Zhou M, Tse C-M, Wang J, Unadkat JD (2009) Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol 296:G910–G922PubMedPubMedCentralCrossRef
Zurück zum Zitat Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19:407–411PubMedCrossRef Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19:407–411PubMedCrossRef
Zurück zum Zitat Grigorian A, Hurford R, Chao Y, Patrick C, Langford TD (2008) Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir. BMC Neurosci 9:27PubMedPubMedCentralCrossRef Grigorian A, Hurford R, Chao Y, Patrick C, Langford TD (2008) Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir. BMC Neurosci 9:27PubMedPubMedCentralCrossRef
Zurück zum Zitat Hashiguchi Y, Hamada A, Shinohara T, Tsuchiya K, Jono H, Saito H (2013) Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. Biochem Biophys Res Commun 439:221–227PubMedCrossRef Hashiguchi Y, Hamada A, Shinohara T, Tsuchiya K, Jono H, Saito H (2013) Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. Biochem Biophys Res Commun 439:221–227PubMedCrossRef
Zurück zum Zitat Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, Group C (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096. doi:10.1212/WNL.0b013e318200d727 PubMedPubMedCentralCrossRef Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, Group C (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 75:2087–2096. doi:10.​1212/​WNL.​0b013e318200d727​ PubMedPubMedCentralCrossRef
Zurück zum Zitat Heaton RK, Franklin DR Jr, Deutsch R, Letendre S, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, Abramson I, Gamst AC, Fennema-Notestine C, Smith DM, Grant I, Group C (2015) Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 60:473–480. doi:10.1093/cid/ciu862 PubMedCrossRef Heaton RK, Franklin DR Jr, Deutsch R, Letendre S, Ellis RJ, Casaletto K, Marquine MJ, Woods SP, Vaida F, Atkinson JH, Marcotte TD, McCutchan JA, Collier AC, Marra CM, Clifford DB, Gelman BB, Sacktor N, Morgello S, Simpson DM, Abramson I, Gamst AC, Fennema-Notestine C, Smith DM, Grant I, Group C (2015) Neurocognitive change in the era of HIV combination antiretroviral therapy: the longitudinal CHARTER study. Clin Infect Dis 60:473–480. doi:10.​1093/​cid/​ciu862 PubMedCrossRef
Zurück zum Zitat Huang W, Eum SY, András IE, Hennig B, Toborek M (2009) PPARα and PPARγ attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J 23:1596–1606PubMedPubMedCentralCrossRef Huang W, Eum SY, András IE, Hennig B, Toborek M (2009) PPARα and PPARγ attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J 23:1596–1606PubMedPubMedCentralCrossRef
Zurück zum Zitat Jamaluddin MS, Lin PH, Yao Q, Chen C (2010) Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. Atherosclerosis 208:104–111PubMedCrossRef Jamaluddin MS, Lin PH, Yao Q, Chen C (2010) Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. Atherosclerosis 208:104–111PubMedCrossRef
Zurück zum Zitat James CW, McNelis KC, Matalia MD, Cohen DM, Szabo S (2002) Central nervous system toxicity and amprenavir oral solution. Ann Pharmacother 36:174PubMedCrossRef James CW, McNelis KC, Matalia MD, Cohen DM, Szabo S (2002) Central nervous system toxicity and amprenavir oral solution. Ann Pharmacother 36:174PubMedCrossRef
Zurück zum Zitat Jensen BK, Monnerie H, Mannell MV, Gannon PJ, Espinoza CA, Erickson MA, Bruce-Keller AJ, Gelman BB, Briand LA, Pierce RC, Jordan-Sciutto KL, Grinspan JB (2015) Altered oligodendrocyte maturation and myelin maintenance: the role of antiretrovirals in HIV-associated neurocognitive disorders. J Neuropathol Exp Neurol 74:1093–1118. doi:10.1097/NEN.0000000000000255 PubMedCrossRef Jensen BK, Monnerie H, Mannell MV, Gannon PJ, Espinoza CA, Erickson MA, Bruce-Keller AJ, Gelman BB, Briand LA, Pierce RC, Jordan-Sciutto KL, Grinspan JB (2015) Altered oligodendrocyte maturation and myelin maintenance: the role of antiretrovirals in HIV-associated neurocognitive disorders. J Neuropathol Exp Neurol 74:1093–1118. doi:10.​1097/​NEN.​0000000000000255​ PubMedCrossRef
Zurück zum Zitat Jin J, Grimmig B, Izzo J, Brown LA, Hudson C, Smith AJ, Tan J, Bickford PC, Giunta B (2016) HIV non-nucleoside reverse transcriptase inhibitor efavirenz reduces neural stem cell proliferation in vitro and in vivo. Cell Transplant. doi:10.3727/096368916X691457 PubMed Jin J, Grimmig B, Izzo J, Brown LA, Hudson C, Smith AJ, Tan J, Bickford PC, Giunta B (2016) HIV non-nucleoside reverse transcriptase inhibitor efavirenz reduces neural stem cell proliferation in vitro and in vivo. Cell Transplant. doi:10.​3727/​096368916X691457​ PubMed
Zurück zum Zitat Kakuda TN, Scholler-Gyure M, Hoetelmans RM (2010) Clinical perspective on antiretroviral drug–drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther 15:817–829. doi:10.3851/IMP1652 PubMedCrossRef Kakuda TN, Scholler-Gyure M, Hoetelmans RM (2010) Clinical perspective on antiretroviral drug–drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine. Antivir Ther 15:817–829. doi:10.​3851/​IMP1652 PubMedCrossRef
Zurück zum Zitat Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y (2007) HIV-1 gp120 compromises blood–brain barrier integrity and enhance monocyte migration across blood–brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab 27:123–134PubMedCrossRef Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y (2007) HIV-1 gp120 compromises blood–brain barrier integrity and enhance monocyte migration across blood–brain barrier: implication for viral neuropathogenesis. J Cereb Blood Flow Metab 27:123–134PubMedCrossRef
Zurück zum Zitat Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654–660PubMedPubMedCentral Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW, Leonard JM (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654–660PubMedPubMedCentral
Zurück zum Zitat Kis O, Robillard K, Chan GN, Bendayan R (2010) The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31:22–35PubMedCrossRef Kis O, Robillard K, Chan GN, Bendayan R (2010) The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters. Trends Pharmacol Sci 31:22–35PubMedCrossRef
Zurück zum Zitat Kline ER, Sutliff RL (2008) The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med 56:752–769PubMedPubMedCentralCrossRef Kline ER, Sutliff RL (2008) The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med 56:752–769PubMedPubMedCentralCrossRef
Zurück zum Zitat Kline ER, Bassit L, Hernandez-Santiago BI, Detorio MA, Liang B, Kleinhenz DJ, Walp ER, Dikalov S, Jones DP, Schinazi RF (2009) Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction. Cardiovasc Toxicol 9:1–12PubMedCrossRef Kline ER, Bassit L, Hernandez-Santiago BI, Detorio MA, Liang B, Kleinhenz DJ, Walp ER, Dikalov S, Jones DP, Schinazi RF (2009) Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction. Cardiovasc Toxicol 9:1–12PubMedCrossRef
Zurück zum Zitat Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423–431PubMed Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423–431PubMed
Zurück zum Zitat Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug–drug interaction. Drug Metab Dispos 27:902–908PubMed Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug–drug interaction. Drug Metab Dispos 27:902–908PubMed
Zurück zum Zitat Lai Y, Tse CM, Unadkat JD (2004) Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 279:4490–4497. doi:10.1074/jbc.M307938200 PubMedCrossRef Lai Y, Tse CM, Unadkat JD (2004) Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 279:4490–4497. doi:10.​1074/​jbc.​M307938200 PubMedCrossRef
Zurück zum Zitat Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, Group TS (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175–2185. doi:10.1056/NEJMoa035026 PubMedCrossRef Lalezari JP, Henry K, O’Hearn M, Montaner JS, Piliero PJ, Trottier B, Walmsley S, Cohen C, Kuritzkes DR, Eron JJ Jr, Chung J, DeMasi R, Donatacci L, Drobnes C, Delehanty J, Salgo M, Group TS (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175–2185. doi:10.​1056/​NEJMoa035026 PubMedCrossRef
Zurück zum Zitat Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M, Group TS (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348:2186–2195. doi:10.1056/NEJMoa035211 PubMedCrossRef Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, Katlama C, Stellbrink HJ, Delfraissy JF, Lange J, Huson L, DeMasi R, Wat C, Delehanty J, Drobnes C, Salgo M, Group TS (2003) Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 348:2186–2195. doi:10.​1056/​NEJMoa035211 PubMedCrossRef
Zurück zum Zitat Lee H, Hanes J, Johnson KA (2003) Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42:14711–14719. doi:10.1021/bi035596s PubMedCrossRef Lee H, Hanes J, Johnson KA (2003) Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42:14711–14719. doi:10.​1021/​bi035596s PubMedCrossRef
Zurück zum Zitat Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19:137–142PubMedPubMedCentral Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19:137–142PubMedPubMedCentral
Zurück zum Zitat Letendre SL, Ellis RJ, Ances BM, McCutchan JA (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18:45–55PubMed Letendre SL, Ellis RJ, Ances BM, McCutchan JA (2010) Neurologic complications of HIV disease and their treatment. Top HIV Med 18:45–55PubMed
Zurück zum Zitat Lewis W (2003) Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antivir Res 58:189–197PubMedCrossRef Lewis W (2003) Mitochondrial dysfunction and nucleoside reverse transcriptase inhibitor therapy: experimental clarifications and persistent clinical questions. Antivir Res 58:189–197PubMedCrossRef
Zurück zum Zitat Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA (1998) Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26:609–616PubMed Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA (1998) Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26:609–616PubMed
Zurück zum Zitat Liu Z-J, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M (2003) Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 23:14–25PubMedPubMedCentralCrossRef Liu Z-J, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M (2003) Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 23:14–25PubMedPubMedCentralCrossRef
Zurück zum Zitat Ma Q, Vaida F, Wong J, Sanders CA, Kao YT, Croteau D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, Morgello S, Simpson DM, Heaton RK, Grant I, Letendre SL, Group C (2016) Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol 22:170–178. doi:10.1007/s13365-015-0382-7 PubMedCrossRef Ma Q, Vaida F, Wong J, Sanders CA, Kao YT, Croteau D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, Morgello S, Simpson DM, Heaton RK, Grant I, Letendre SL, Group C (2016) Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients. J Neurovirol 22:170–178. doi:10.​1007/​s13365-015-0382-7 PubMedCrossRef
Zurück zum Zitat Mahajan SD, Roy I, Xu G, Yong KT, Ding H, Aalinkeel R, Reynolds J, Sykes D, Nair BB, Lin EY, Prasad PN, Schwartz SA (2010) Enhancing the delivery of anti retroviral drug “Saquinavir” across the blood brain barrier using nanoparticles. Curr HIV Res 8:396–404PubMedPubMedCentralCrossRef Mahajan SD, Roy I, Xu G, Yong KT, Ding H, Aalinkeel R, Reynolds J, Sykes D, Nair BB, Lin EY, Prasad PN, Schwartz SA (2010) Enhancing the delivery of anti retroviral drug “Saquinavir” across the blood brain barrier using nanoparticles. Curr HIV Res 8:396–404PubMedPubMedCentralCrossRef
Zurück zum Zitat Malaty LI, Kuper JJ (1999) Drug interactions of HIV protease inhibitors. Drug Saf 20:147–169PubMedCrossRef Malaty LI, Kuper JJ (1999) Drug interactions of HIV protease inhibitors. Drug Saf 20:147–169PubMedCrossRef
Zurück zum Zitat Manda VK, Mittapalli RK, Geldenhuys WJ, Lockman PR (2010) Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood–brain barrier integrity. J Neurochem 115:515–525PubMedCrossRef Manda VK, Mittapalli RK, Geldenhuys WJ, Lockman PR (2010) Chronic exposure to nicotine and saquinavir decreases endothelial Notch-4 expression and disrupts blood–brain barrier integrity. J Neurochem 115:515–525PubMedCrossRef
Zurück zum Zitat Manda KR, Banerjee A, Banks WA, Ercal N (2011) Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood–brain barrier endothelial cells. Free Radic Biol Med 50:801–810PubMedCrossRef Manda KR, Banerjee A, Banks WA, Ercal N (2011) Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood–brain barrier endothelial cells. Free Radic Biol Med 50:801–810PubMedCrossRef
Zurück zum Zitat Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K, Team ACTGS (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359–1366. doi:10.1097/QAD.0b013e32832c4152 PubMedPubMedCentralCrossRef Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K, Team ACTGS (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359–1366. doi:10.​1097/​QAD.​0b013e32832c4152​ PubMedPubMedCentralCrossRef
Zurück zum Zitat Maxwell S, Scheftner WA, Kessler HA, Busch K (1988) Manic syndrome associated with zidovudine treatment. JAMA 259:3406–3407PubMedCrossRef Maxwell S, Scheftner WA, Kessler HA, Busch K (1988) Manic syndrome associated with zidovudine treatment. JAMA 259:3406–3407PubMedCrossRef
Zurück zum Zitat Meyer RP, Gehlhaus M, Knoth R, Volk B (2007) Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab 8:297–306PubMedCrossRef Meyer RP, Gehlhaus M, Knoth R, Volk B (2007) Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab 8:297–306PubMedCrossRef
Zurück zum Zitat Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA (2012) The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 64:803–833. doi:10.1124/pr.111.005553 PubMedCrossRef Michaud V, Bar-Magen T, Turgeon J, Flockhart D, Desta Z, Wainberg MA (2012) The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev 64:803–833. doi:10.​1124/​pr.​111.​005553 PubMedCrossRef
Zurück zum Zitat Mondal D, Pradhan L, Ali M, Agrawal KC (2004) HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells. Cardiovasc Toxicol 4:287–302PubMedCrossRef Mondal D, Pradhan L, Ali M, Agrawal KC (2004) HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells. Cardiovasc Toxicol 4:287–302PubMedCrossRef
Zurück zum Zitat Morlese JF, Qazi NA, Gazzard BG, Nelson MR (2002) Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors? AIDS 16:1840–1841PubMedCrossRef Morlese JF, Qazi NA, Gazzard BG, Nelson MR (2002) Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors? AIDS 16:1840–1841PubMedCrossRef
Zurück zum Zitat Nag S, Kapadia A, Stewart D (2011) Review: molecular pathogenesis of blood–brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol 37:3–23PubMedCrossRef Nag S, Kapadia A, Stewart D (2011) Review: molecular pathogenesis of blood–brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol 37:3–23PubMedCrossRef
Zurück zum Zitat Noseda M, Chang L, McLean G, Grim JE, Clurman BE, Smith LL, Karsan A (2004) Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol 24:8813–8822PubMedPubMedCentralCrossRef Noseda M, Chang L, McLean G, Grim JE, Clurman BE, Smith LL, Karsan A (2004) Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol Cell Biol 24:8813–8822PubMedPubMedCentralCrossRef
Zurück zum Zitat O’Mahony SM, Myint AM, Steinbusch H, Leonard BE (2005) Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. NeuroImmunoModulation 12:293–298. doi:10.1159/000087107 PubMedCrossRef O’Mahony SM, Myint AM, Steinbusch H, Leonard BE (2005) Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. NeuroImmunoModulation 12:293–298. doi:10.​1159/​000087107 PubMedCrossRef
Zurück zum Zitat Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105:3879–3884. doi:10.1073/pnas.0800050105 PubMedPubMedCentralCrossRef Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS (2008) Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA 105:3879–3884. doi:10.​1073/​pnas.​0800050105 PubMedPubMedCentralCrossRef
Zurück zum Zitat Pedrol E, Llibre JM, Tasias M, Curran A, Guardiola JM, Deig E, Guelar A, Martinez-Madrid O, Tikhomirova L, Ramirez R, Group RS (2015) Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. HIV Med 16:628–634. doi:10.1111/hiv.12298 PubMedCrossRef Pedrol E, Llibre JM, Tasias M, Curran A, Guardiola JM, Deig E, Guelar A, Martinez-Madrid O, Tikhomirova L, Ramirez R, Group RS (2015) Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study. HIV Med 16:628–634. doi:10.​1111/​hiv.​12298 PubMedCrossRef
Zurück zum Zitat Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood–brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1:223–236PubMedCrossRef Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD (2006) Blood–brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol 1:223–236PubMedCrossRef
Zurück zum Zitat Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg M (2014) Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. Mol Psychiatry 19:733–741. doi:10.1038/mp.2013.89 PubMedCrossRef Persson A, Sim SC, Virding S, Onishchenko N, Schulte G, Ingelman-Sundberg M (2014) Decreased hippocampal volume and increased anxiety in a transgenic mouse model expressing the human CYP2C19 gene. Mol Psychiatry 19:733–741. doi:10.​1038/​mp.​2013.​89 PubMedCrossRef
Zurück zum Zitat Pettersen JA, Jones G, Worthington C, Krentz HB, Keppler OT, Hoke A, Gill MJ, Power C (2006) Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 59:816–824. doi:10.1002/ana.20816 PubMedCrossRef Pettersen JA, Jones G, Worthington C, Krentz HB, Keppler OT, Hoke A, Gill MJ, Power C (2006) Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity. Ann Neurol 59:816–824. doi:10.​1002/​ana.​20816 PubMedCrossRef
Zurück zum Zitat Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging 12:295–312PubMedCrossRef Price JL, Davis PB, Morris JC, White DL (1991) The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging 12:295–312PubMedCrossRef
Zurück zum Zitat Ragin AB, Storey P, Cohen BA, Epstein LG, Edelman RR (2004) Whole brain diffusion tensor imaging in HIV-associated cognitive impairment. AJNR Am J Neuroradiol 25:195–200PubMedPubMedCentral Ragin AB, Storey P, Cohen BA, Epstein LG, Edelman RR (2004) Whole brain diffusion tensor imaging in HIV-associated cognitive impairment. AJNR Am J Neuroradiol 25:195–200PubMedPubMedCentral
Zurück zum Zitat Renn CL, Leitch CC, Lessans S, Rhee P, McGuire WC, Smith BA, Traub RJ, Dorsey SG (2011) Brain-derived neurotrophic factor modulates antiretroviral-induced mechanical allodynia in the mouse. J Neurosci Res 89:1551–1565. doi:10.1002/jnr.22685 PubMedCrossRef Renn CL, Leitch CC, Lessans S, Rhee P, McGuire WC, Smith BA, Traub RJ, Dorsey SG (2011) Brain-derived neurotrophic factor modulates antiretroviral-induced mechanical allodynia in the mouse. J Neurosci Res 89:1551–1565. doi:10.​1002/​jnr.​22685 PubMedCrossRef
Zurück zum Zitat Robertson K, Su Z, Margolis D, Krambrink A, Havlir D, Evans S, Skiest D, Team AS (2010) Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74:1260–1266PubMedPubMedCentralCrossRef Robertson K, Su Z, Margolis D, Krambrink A, Havlir D, Evans S, Skiest D, Team AS (2010) Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 74:1260–1266PubMedPubMedCentralCrossRef
Zurück zum Zitat Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, Telenti A, Swiss HIVCS (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 15:1–5PubMedCrossRef Rotger M, Colombo S, Furrer H, Bleiber G, Buclin T, Lee BL, Keiser O, Biollaz J, Decosterd L, Telenti A, Swiss HIVCS (2005) Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 15:1–5PubMedCrossRef
Zurück zum Zitat Rumbaugh JA, Nath A (2006) Developments in HIV neuropathogenesis. Curr Pharm Des 12:1023–1044PubMedCrossRef Rumbaugh JA, Nath A (2006) Developments in HIV neuropathogenesis. Curr Pharm Des 12:1023–1044PubMedCrossRef
Zurück zum Zitat Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136–142. doi:10.1080/13550280290049615 PubMedCrossRef Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136–142. doi:10.​1080/​1355028029004961​5 PubMedCrossRef
Zurück zum Zitat Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA (2010) CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 54:285–289. doi:10.1097/QAI.0b013e3181bf648a PubMedPubMedCentralCrossRef Saitoh A, Capparelli E, Aweeka F, Sarles E, Singh KK, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA (2010) CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 54:285–289. doi:10.​1097/​QAI.​0b013e3181bf648a​ PubMedPubMedCentralCrossRef
Zurück zum Zitat Sanchez Martin A, Cabrera Figueroa S, Cruz Guerrero R, Hurtado LP, Hurle AD, Carracedo Alvarez A (2013) Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics 14:1167–1178. doi:10.2217/pgs.13.111 PubMedCrossRef Sanchez Martin A, Cabrera Figueroa S, Cruz Guerrero R, Hurtado LP, Hurle AD, Carracedo Alvarez A (2013) Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics 14:1167–1178. doi:10.​2217/​pgs.​13.​111 PubMedCrossRef
Zurück zum Zitat Sanchez AB, Varano GP, de Rozieres CM, Maung R, Catalan IC, Dowling CC, Sejbuk NE, Hoefer MM, Kaul M (2016) Antiretrovirals, methamphetamine, and HIV-1 envelope protein gp120 compromise neuronal energy homeostasis in association with various degrees of synaptic and neuritic damage. Antimicrob Agents Chemother 60:168–179. doi:10.1128/AAC.01632-15 CrossRef Sanchez AB, Varano GP, de Rozieres CM, Maung R, Catalan IC, Dowling CC, Sejbuk NE, Hoefer MM, Kaul M (2016) Antiretrovirals, methamphetamine, and HIV-1 envelope protein gp120 compromise neuronal energy homeostasis in association with various degrees of synaptic and neuritic damage. Antimicrob Agents Chemother 60:168–179. doi:10.​1128/​AAC.​01632-15 CrossRef
Zurück zum Zitat Saracchini S, Vaccher E, Covezzi E, Tortorici G, Carbone A, Tirelli U (1989) Lethal neurotoxicity associated to azidothymidine therapy. J Neurol Neurosurg Psychiatry 52:544–545PubMedPubMedCentralCrossRef Saracchini S, Vaccher E, Covezzi E, Tortorici G, Carbone A, Tirelli U (1989) Lethal neurotoxicity associated to azidothymidine therapy. J Neurol Neurosurg Psychiatry 52:544–545PubMedPubMedCentralCrossRef
Zurück zum Zitat Sharma P, Garg S (2010) Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 62:491–502PubMedCrossRef Sharma P, Garg S (2010) Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. Adv Drug Deliv Rev 62:491–502PubMedCrossRef
Zurück zum Zitat Simioni S, Cavassini M, Annoni JM, Abraham AR, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250. doi:10.1097/QAD.0b013e3283354a7b PubMed Simioni S, Cavassini M, Annoni JM, Abraham AR, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250. doi:10.​1097/​QAD.​0b013e3283354a7b​ PubMed
Zurück zum Zitat Sutliff RL, Dikalov S, Weiss D, Parker J, Raidel S, Racine AK, Russ R, Haase CP, Taylor WR, Lewis W (2002) Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am J Physiol Heart Circu Physiol 283:H2363–H2370CrossRef Sutliff RL, Dikalov S, Weiss D, Parker J, Raidel S, Racine AK, Russ R, Haase CP, Taylor WR, Lewis W (2002) Nucleoside reverse transcriptase inhibitors impair endothelium-dependent relaxation by increasing superoxide. Am J Physiol Heart Circu Physiol 283:H2363–H2370CrossRef
Zurück zum Zitat Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, Lievano F, Lehman HP, Mast TC, Nguyen BY (2011) Long-term safety from the raltegravir clinical development program. Curr HIV Res 9:40–53PubMedPubMedCentralCrossRef Teppler H, Brown DD, Leavitt RY, Sklar P, Wan H, Xu X, Lievano F, Lehman HP, Mast TC, Nguyen BY (2011) Long-term safety from the raltegravir clinical development program. Curr HIV Res 9:40–53PubMedPubMedCentralCrossRef
Zurück zum Zitat Toborek M, Lee YW, Flora G, Pu H, András IE, Wylegala E, Hennig B, Nath A (2005) Mechanisms of the blood–brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 25:181–199PubMedCrossRef Toborek M, Lee YW, Flora G, Pu H, András IE, Wylegala E, Hennig B, Nath A (2005) Mechanisms of the blood–brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 25:181–199PubMedCrossRef
Zurück zum Zitat Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S (2004) Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322–1326. doi:10.1016/j.bbrc.2004.05.116 PubMedCrossRef Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M, Kuwahara T, Shirasaka T, Kimura S, Oka S (2004) Homozygous CYP2B6*6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 319:1322–1326. doi:10.​1016/​j.​bbrc.​2004.​05.​116 PubMedCrossRef
Zurück zum Zitat van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM (2001) Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 6:201–229PubMed van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM (2001) Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 6:201–229PubMed
Zurück zum Zitat van Praag RM, Weverling GJ, Portegies P, Jurriaans S, Zhou X-J, Turner-Foisy ML, Sommadossi J-P, Burger DM, Lange JM, Hoetelmans RM (2000) Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. Aids 14:1187–1194PubMedCrossRef van Praag RM, Weverling GJ, Portegies P, Jurriaans S, Zhou X-J, Turner-Foisy ML, Sommadossi J-P, Burger DM, Lange JM, Hoetelmans RM (2000) Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. Aids 14:1187–1194PubMedCrossRef
Zurück zum Zitat Venhoff N, Lebrecht D, Deveaud C, Beauvoit B, Bonnet J, Muller K, Kirschner J, Venhoff AC, Walker UA (2010) Oral uridine supplementation antagonizes the peripheral neuropathy and encephalopathy induced by antiretroviral nucleoside analogues. AIDS 24:345–352. doi:10.1097/QAD.0b013e328335cdea PubMedCrossRef Venhoff N, Lebrecht D, Deveaud C, Beauvoit B, Bonnet J, Muller K, Kirschner J, Venhoff AC, Walker UA (2010) Oral uridine supplementation antagonizes the peripheral neuropathy and encephalopathy induced by antiretroviral nucleoside analogues. AIDS 24:345–352. doi:10.​1097/​QAD.​0b013e328335cdea​ PubMedCrossRef
Zurück zum Zitat Villa G, Solida A, Moro E, Tavolozza M, Antinori A, De Luca A, Murri R, Tamburrini E (1996) Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study. Eur Neurol 36:125–133PubMedCrossRef Villa G, Solida A, Moro E, Tavolozza M, Antinori A, De Luca A, Murri R, Tamburrini E (1996) Cognitive impairment in asymptomatic stages of HIV infection. A longitudinal study. Eur Neurol 36:125–133PubMedCrossRef
Zurück zum Zitat Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ (2003) Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. Aids 17:1092–1094PubMedCrossRef Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ (2003) Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. Aids 17:1092–1094PubMedCrossRef
Zurück zum Zitat Wang X, Chai H, Yao Q, Chen C (2007) Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction JAIDS. J Acquir Immune Defic Syndr 44:493–499PubMedCrossRef Wang X, Chai H, Yao Q, Chen C (2007) Molecular mechanisms of HIV protease inhibitor-induced endothelial dysfunction JAIDS. J Acquir Immune Defic Syndr 44:493–499PubMedCrossRef
Zurück zum Zitat Wang X, Chai H, Lin PH, Yao Q, Chen C (2009) Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 174:771–781PubMedPubMedCentralCrossRef Wang X, Chai H, Lin PH, Yao Q, Chen C (2009) Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol 174:771–781PubMedPubMedCentralCrossRef
Zurück zum Zitat Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300. doi:10.1124/jpet.103.049601 PubMedCrossRef Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287–300. doi:10.​1124/​jpet.​103.​049601 PubMedCrossRef
Zurück zum Zitat Watkins CC, Treisman GJ (2015) Cognitive impairment in patients with AIDS—prevalence and severity. HIV AIDS (Auckl) 7:35–47. doi:10.2147/HIV.S39665 Watkins CC, Treisman GJ (2015) Cognitive impairment in patients with AIDS—prevalence and severity. HIV AIDS (Auckl) 7:35–47. doi:10.​2147/​HIV.​S39665
Zurück zum Zitat Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, de Oliveira AP, Pumpradit W, Shlay JC, El-Sadr W, Price RW, Group ISS (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75:864–873. doi:10.1212/WNL.0b013e3181f11bd8 PubMedPubMedCentralCrossRef Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, de Oliveira AP, Pumpradit W, Shlay JC, El-Sadr W, Price RW, Group ISS (2010) Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 75:864–873. doi:10.​1212/​WNL.​0b013e3181f11bd8​ PubMedPubMedCentralCrossRef
Zurück zum Zitat Xu C, Desta Z (2013) In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet 28:362–371PubMedPubMedCentralCrossRef Xu C, Desta Z (2013) In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19. Drug Metab Pharmacokinet 28:362–371PubMedPubMedCentralCrossRef
Zurück zum Zitat Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42:52–60. doi:10.1097/01.qai.0000219774.20174.64 PubMed Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 42:52–60. doi:10.​1097/​01.​qai.​0000219774.​20174.​64 PubMed
Zurück zum Zitat Zhong D, Lu H, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C (2002) HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 22:1560–1566PubMedCrossRef Zhong D, Lu H, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C (2002) HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 22:1560–1566PubMedCrossRef
Zurück zum Zitat Zlokovic BV (2008) The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201PubMedCrossRef Zlokovic BV (2008) The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201PubMedCrossRef
Metadaten
Titel
Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics
verfasst von
Ankit Shah
Mohitkumar R. Gangwani
Nitish S. Chaudhari
Alexy Glazyrin
Hari K. Bhat
Anil Kumar
Publikationsdatum
01.11.2016
Verlag
Springer US
Erschienen in
Neurotoxicity Research / Ausgabe 4/2016
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI
https://doi.org/10.1007/s12640-016-9646-0

Weitere Artikel der Ausgabe 4/2016

Neurotoxicity Research 4/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Neurologie

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.